Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Opinion
Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag
Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
Novo Nordisk CEO Faces Senate Questions Over High Prices Of Ozempic And Wegovy In US
Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in
Hosted on MSN2d
Why Is Ozempic So Expensive? Novo Nordisk Blames Prescription Drug Middlemen
A U.S. Senate panel criticized Novo Nordisk for the high prices of Ozempic and Wegovy. Novo Nordisk CEO blamed high prices on ...
Drugs like Ozempic are now more popular than insulin for treating diabetes
It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
Novo Nordisk Has Mitigation Plans to Minimize Disruption From Port Strikes, CNBC Reports
(Reuters) - Danish drugmaker Novo Nordisk has mitigation plans in place to minimize or prevent any disruption to its ...
Butler Eagle2d
Who’s really keeping Ozempic and Wegovy prices so high?
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...